SecBot SecBot
Biotech Drug Report Generated Aug 28, 2026

CTX340

CRSP·CRISPR Therapeutics AG
NEUTRAL
Drug Impact Rating1/10
Trial phase
Not stated
Time to market
Not stated
Why 1/10
No dated catalyst (PDUFA, pivotal readout, or regulatory decision) can be identified for CTX340 within the next ~12 months because the drug does not appear in any clinical trial registry, FDA database, or company disclosure. The impact score defaults to the lowest tier for an unidentifiable/undisclosed program.
Actionable Insight NEUTRAL

CTX340 cannot be found in any public database, investors should not trade CRSP based on this drug name until the company explicitly discloses a program by this designation. For CRISPR Therapeutics as a whole, the key near-term value drivers are CASGEVY commercial ramp (Q2 2026 revenue $76M, +151% YoY) and any data readouts from the CTX131 Phase 2 CAR-T program, not an unidentifiable CTX340.

Price Chart

Loading chart...

Executive Summary

CTX340 is a drug candidate attributed to CRISPR Therapeutics AG (Nasdaq: CRSP) based on a filing hint, but no evidence of this specific program exists in any available database, including clinical trial registries, FDA records, SEC filings, press releases, or analyst coverage. CRISPR Therapeutics is a well-funded, publicly traded gene-editing company with one approved product (CASGEVY for sickle cell disease and beta-thalassemia) and a Phase 2 CAR-T candidate (CTX131), but CTX340 appears to be either a very early preclinical program not yet publicly disclosed, a mistyped name, or a non-existent designation. The company trades at ~$59/share with a mean analyst price target of ~$87.56 (34.7% implied upside) and has 17 Buy/Strong Buy ratings vs. 12 Holds and 0 Sells.

How It Works

Unknown. CRISPR Therapeutics specializes in CRISPR/Cas9 gene-editing therapies. Based on the company's naming convention ("CTX" prefix), CTX340 would likely be a gene-editing therapeutic, but its specific mechanism, target, and indication cannot be determined from available data.

Trial Status

No clinical trial records, FDA data, press releases, or SEC filings referencing "CTX340" were found in any available database. CRISPR Therapeutics' publicly known pipeline includes the approved gene therapy CASGEVY (CTX001/exagamglogene autotemcel) and the Phase 2 CAR-T candidate CTX131, but no program designated CTX340 appears in any ingested source.

The Two-Sided Case

▲ Bull Case2
CRISPR Therapeutics has a validated platform with the approved drug CASGEVY (CTX001), demonstrating its ability to bring gene-editing therapies to market, any new pipeline candidate benefits from this infrastructure.
The company reported Q2 2026 CASGEVY revenue of $76M (+151% YoY) and beat consensus EPS estimates, indicating strong commercial execution that could fund pipeline expansion.
▼ Bear Case3
CTX340 is not referenced in any clinical trial, FDA filing, press release, or SEC document in available databases, it may be a preclinical program years away from human testing, or the name may be incorrect/mistyped.
CRISPR Therapeutics faces significant competition in the gene-editing space from companies like Vertex (VRTX), Intellia (NTLA), Editas (EDIT), and Beam (BEAM), any of which could have overlapping pipeline programs.
With no publicly disclosed data on CTX340, there is no basis to evaluate its therapeutic potential, safety, or market opportunity.

Upcoming Catalysts

  • No catalysts identified for CTX340, the drug is not found in any clinical trial registry, FDA database, or company disclosure.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CRISPR Therapeutics AG PRESS-RELEASE CRSP ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 globenewswire.com3 globenewswire.com